Jobs / United States / Astrazeneca Pharmaceuticals Lp
Medical Science Liaison - Pipeline, Immunology (California)
Astrazeneca Pharmaceuticals Lp · 🇺🇸 4 Locations
Sponsorship verdict
Sponsorship possible
One solid signal, not two — worth applying, and worth asking about sponsorship early.
- Employer is on a government sponsor recordThe US Department of Labor certified 99 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 31 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
- The posting doesn’t mention sponsorshipSilence isn’t a refusal — ask the recruiter before investing much time.
- No salary bar for this routeH-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area. Cap-subject employers enter a lottery weighted by wage level. Source: https://www.federalregister.gov/documents/2025/12/29/2025-23853/weighted-selection-process-for-registrants-and-petitioners-seeking-to-file-cap-subject-h-1b, rules effective 2026-02-27.
- What Astrazeneca Pharmaceuticals Lp paid sponsored hires in similar roles15 certified filings for “Associate Director Oncology Outcomes Research” (Medical Scientists, Except Epidemiologists) in MD: $126k–$185k, median $140k. Most were filed at wage level II (47%) — 2 lottery entries, ≈31% projected selection odds for cap-subject employers. Source: US Department of Labor LCA disclosure data (Oct 2025 – Jun 2026).
- Confirmed live todayWhen a source last listed this job as open.
US H-1B: cap-subject employers enter a lottery weighted by wage level — Level I gets 1 entry, Level IV gets 4 (DHS projected selection odds ≈15% at Level I to ≈61% at Level IV). Universities and non-profit research employers are cap-exempt. The $100,000 fee for new petitions from abroad is currently blocked by a court order (appeal pending).
A verdict summarises public evidence; it is not legal advice and never a guarantee — the employer and the immigration authority decide. Sign in to factor in where you can already work.
Or apply yourself on the official page →
Sponsor Radar — Astrazeneca Pharmaceuticals Lp
The US Department of Labor certified 99 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 31 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
Past sponsorship or register membership never guarantees sponsorship for this vacancy or for you. Full Sponsor Radar for Astrazeneca Pharmaceuticals Lp →
About the role
At AstraZeneca we turn ideas into life changing medicines. Working here means being entrepreneurial, thinking big and working together to make the impossible a reality. We’re focused on the potential of science to address the unmet needs of patients around the world. We commit to those areas where we believe we can change the course of medicine and bring big new ideas to life. As an Immunology Pipeline MSL , you’ll play a pivotal role in advancing our science to bring life-changing medicines to patients. AstraZeneca has a broad and deep pipeline of next-generation medicines in Immunology . We are seeking highly motivated and experienced individuals to support scientific dialogue, drive clinical trial engagement and foster collaborations across AstraZeneca’s i mmunology pipeline . Your work will facilitate the running of current and future clinical programs across multiple autoimmune disease areas with a focus on rheumatology and gastroenterology. The Immunology Pipeline MSL is a field-based professional with scientific, clinical and therapeutic area expertise , responsible for building external r elationships with identified and emerging health care providers and investigators and providing scientific and clinical trial support to advance AstraZeneca’s immunology pipeline. You will be working closely with global and country R&D teams , as well as medical affairs teams working on established products, to ensure strategic, cohesive account engagement and a unified external presence . Must live in the territory or following cites/states: Los Angeles, San Diego, San Francisco, CA Key Responsibilities Scientific e ngagement and r elationship b uilding : • Deliver enhanced scientific and medical exchange at the portfolio - level , including Cell Therapy , T cell engagers and other novel immunomodulatory monoclonal antibodies and small molecules • Build strong, non-promotional relationships with investigators, study staff and referring HCPs at investigational sites and key scientific centers to support active and planned AZ-sponsored immunology trials. • I dentify stakeholders and opportunities for engagement and collaborations with R&D and medical affairs • Educate clinical trial sites and referring physicians on AZ’s immunology portfolio and study designs to enhance understanding of objectives and drive clarity in patient identification across multiple AZ studies. Site s trategy , f easibility and trial enrolment : • Map and engage disease, community, and investigator networks; identify new sites and referral pathways . • S upport feasibility by assessing patient pools, standard-of-care patterns, competing trials and operational capabilities. • Obtain , synthesize and share insights with R&D to inform protocol design, site strategy, and recruitment tactics. • In collaboration with Site Management and Monitoring ( SMM ), proactively explore enrolment and screening barriers and support clinical trial recruitment and retention; collaborate with clinical operations to identify and facilitate resolution of investigator site issues. Essential Requirements • Advanced degree in a scientific discipline e.g., MD, DO, PharmD, PhD, NP, PA-C. • Minimum of 2 years field medical experience e.g. MSL or Clinical Trial Liaison role and/or minimum of 2 years clinical trial research experience within an academic, healthcare system or industry setting. • Demonstrated excellence in scientific communication across different audiences . Proficiency in developing and